V
Vanaja Kumar
Researcher at Indian Council of Medical Research
Publications - 72
Citations - 1864
Vanaja Kumar is an academic researcher from Indian Council of Medical Research. The author has contributed to research in topics: Mycobacterium tuberculosis & Mycobacteriophage. The author has an hindex of 18, co-authored 70 publications receiving 1733 citations.
Papers
More filters
Journal ArticleDOI
Origins of Highly Mosaic Mycobacteriophage Genomes
Marisa L. Pedulla,Michael E. Ford,Jennifer M. Houtz,Tharun Karthikeyan,Curtis Wadsworth,John A. Lewis,Debbie Jacobs-Sera,Jacob Falbo,Joseph Gross,Nicholas R. Pannunzio,William J. Brucker,Vanaja Kumar,Jayasankar Kandasamy,Lauren Keenan,Svetoslav Bardarov,Jordan Kriakov,Jeffrey G. Lawrence,William R. Jacobs,Roger W. Hendrix,Graham F. Hatfull +19 more
TL;DR: The genomic sequences of ten newly isolated mycobacteriophages suggest that the bacteriophage population as a whole is amazingly diverse and may represent the largest unexplored reservoir of sequence information in the biosphere.
Journal ArticleDOI
Exploring the Mycobacteriophage Metaproteome: Phage Genomics as an Educational Platform
Graham F. Hatfull,Marisa L. Pedulla,Deborah Jacobs-Sera,Pauline M Cichon,Amy Foley,Michael E. Ford,Rebecca M Gonda,Jennifer M. Houtz,Andrew J. Hryckowian,Vanessa A Kelchner,Swathi Namburi,Kostandin V Pajcini,Mark G Popovich,Donald T Schleicher,Brian Simanek,Alexis L. Smith,G. Zdanowicz,Vanaja Kumar,Craig L. Peebles,William R. Jacobs,Jeffrey G. Lawrence,Roger W. Hendrix +21 more
TL;DR: The abundance and diversity of phages, the simplicity ofphage isolation, and the relatively small size of phage genomes support bacteriophage isolation and comparative genomic analysis as a highly suitable platform for discovery-based education.
Journal ArticleDOI
Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives.
TL;DR: In order to develop relatively small molecules as antimycobacterial agents, twenty-five chalcones were synthesized, their activity was evaluated, and quantitative structure-activity relationship (QSAR) was developed.
Journal ArticleDOI
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
M. S. Jawahar,Vaithilingam V. Banurekha,Chinnampedu N. Paramasivan,Fathima Rahman,Rajeswari Ramachandran,Perumal Venkatesan,R Balasubramanian,Nagamiah Selvakumar,C Ponnuraja,Allaudeen S. Iliayas,Navaneethapandian P. Gangadevi,Balambal Raman,Dhanaraj Baskaran,Santhanakrishnan Ramesh Kumar,Marimuthu Makesh Kumar,Victor Mohan,Sudha Ganapathy,Vanaja Kumar,Geetha Shanmugam,Niruparani Charles,Murugesan Raja Sakthivel,Kannivelu Jagannath,Chockalingam Chandrasekar,Ramavaram T. Parthasarathy,P R Narayanan +24 more
TL;DR: 4-month thrice-weekly regimens of gatifloxacin or moxiflOxacin with isoniazid, rifampicin and pyrazinamide, were inferior to standard 6-month treatment, in patients with newly diagnosed sputum positive pulmonary TB.
Journal ArticleDOI
Synthesis of quinoline coupled [1,2,3]-triazoles as a promising class of anti-tuberculosis agents
TL;DR: The efficiency and fidelity of the Cu(I)-catalyzed azide-alkyne reaction are substantiated by good yields and exclusive formation of the expected 1,4-disubstituted triazole product.